TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9884259
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir vs. ganciclovir in D-R+ patients
Study: 416989
Drug: Lactobacilli preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacilli preparation (Lactinex)
Study: 30506495
Drug: NESP® (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: NESP® (reference formulation)
Study: 27138652
Drug: Oritavancin 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oritavancin 1600 mg IV over 3 hours
Study: 25681068
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg oral
Study: 24321697
Drug: Coping with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping with negative affect as a target in treatments for marijuana dependence
Study: 7729296
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral magnesium therapy (30 mmol/day)
Study: 2200300
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered at a temperature of 4 degrees C
Study: 2200300
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered at standard temperature (not specified)
Study: 9243749
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B surface antigen vaccine
Study: 30519818
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg, three times a day for 5 days)
Study: 25293351
Drug: DHA (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (400 mg daily)
Study: 17071935
Drug: GV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV plus CDDP 50 mg/m(2) on days 1 and 8 (PGV arm)
Study: 17071935
Drug: GT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GT plus CDDP 50 mg/m(2) on days 1 and 8 (PGT arm)
Study: 11872412
Drug: Thin petrolatum
Normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thin petrolatum (0.1 cc/25 cm2)
Study: 11872412
Drug: Thick petrolatum
Normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thick petrolatum (0.3 cc/25 cm2)
Study: 10458175
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of 2.5 mg of dexamethasone disodium phosphate
Study: 7581970
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of Pyridostigmine (PST)
Study: 7581970
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of Pyridostigmine (PST)
Study: 31119717
Drug: Behavioral physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral physical activity intervention (introductory personal training session followed by eight weekly 15-min PA behavioral coaching sessions)
Study: 23927847
Drug: HP802‐247 (cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP802‐247 (cell therapy)
Study: 16914379
Drug: Monthly nurse‐led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly nurse‐led lifestyle counselling (N=31)
Study: 10971302
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg lamotrigine once daily for 6 days
Study: 10971302
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g lithium gluconate anhydrous every 12 h for 5 days and in the morning of day 6
Study: 3898481
Drug: 150 mOsm/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mOsm/L hypotonic solution
Study: 18971533
Drug: Nattokinase (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nattokinase (2,000 FU/capsule) for 8 weeks
Study: 18971533
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule for 8 weeks
Study: 17674310
Drug: Inactivated poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliovirus vaccine (IPV) only
Study: 17674310
Drug: Oral poliovirus
Normalized name: poliovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral poliovirus vaccine (OPV) only
Study: 9815533
Drug: Broccoli supplements,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli supplements, 3 g/day
Study: 25680893
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg loading dose (LD)/90 mg bid maintenance dose (MD)
Study: 18647232
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 120 mg day(-1) for 6 months
Study: 17050867
Drug: irinotecan 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan 60 mg/m2 and docetaxel 35 mg/m2 with celecoxib 400 mg twice daily
Study: 17050867
Drug: irinotecan 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan 100 mg/m2 and gemcitabine 1,000 mg/m2 with celecoxib 400 mg twice daily
Study: 1448711
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b (10 million U by subcutaneous injection, 3 times a week for 16 weeks)
Study: 4052301
Drug: Diazepam 0.2
Normalized name: diazepam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.2 mg kg‐1
Study: 4052301
Drug: Saline 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.04 ml kg‐1
Study: 31662153
Drug: Stem cell
Normalized name: Stem cells, apheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stem cell therapy (various types including neural, haematopoietic, mesenchymal, differentiated embryonic stem cells, and induced pluripotent stem cells)
Study: 25011604
Drug: Antibiotic mixing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic mixing (9 months) using third- or fourth-generation cephalosporins, piperacillin-tazobactam, and carbapenems during consecutive antibiotic courses.
Study: 25011604
Drug: Antibiotic cycling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic cycling (9 months) using third- or fourth-generation cephalosporins, piperacillin-tazobactam, and carbapenems during consecutive 6-week periods.
Study: 8271805
Drug: Treatment (recovery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (recovery method)
Study: 31175909
Drug: brodalumab 210
Normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: brodalumab 210 mg every 2 weeks after ustekinumab
Study: 29050498
Drug: Program B
Normalized name: ZINC OXIDE 3 g in 100 g / OCTOCRYLENE 6 g in 100 g / ENSULIZOLE 4 g in 100 g / TITANIUM DIOXIDE 2.4 g in 100 g TOPICAL CREAM [NECK DECOLLETE HAND ARM DAY REPARATIVE HYDRATION RESCUE AND REPROGRAM BROAD SPECTRUM SPF 35 SUNSCREEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program B (acute medication restricted to two days/week)
Study: 29050498
Drug: Program A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program A (no analgesics or acute migraine-medication)
Study: 23967632
Drug: Acupuncture +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture + medication group
Study: 24796042
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (triple-strong stimulation, acupuncture, acupuncture + medication)
Study: 23081745
Drug: Fluticasone/formoterol (100/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/formoterol (100/10 or 250/10 μg b.i.d.)
Study: 23081745
Drug: Fluticasone/salmeterol (100/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/salmeterol (100/50 or 250/50 μg b.i.d.)
Study: 19752761
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy and atorvastatin (80 mg/day)
Study: 19752761
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (atorvastatin)
Study: 10188889
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg beta-carotene
Study: 18160753
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg vitamin C
Study: 18190651
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L PEG + E
Study: 9422898
Drug: Dextromethorphan 60
Normalized name: DEXTROMETHORPHAN 60MG/GG 1200MG SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 60 mg
Study: 9422898
Drug: Dextromethorphan 120
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan 120 mg
Study: 3830804
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for 3 years
Study: 3830804
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone for 3 years (27 stage IIID and 36 stage IV patients)
Study: 29866212
Drug: Intervention: Antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Antipsychotic treatment (specifics not provided)
Study: 27609785
Drug: 20 G
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 G vitrectomy plus encircling band (group E1)
Study: 27609785
Drug: 20 G
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 G vitrectomy without any buckle (group C)
Study: 20170514
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of PEG‐IFN‐alpha-2a (180 ug/week) and ribavirin (800‐1200 mg/day)
Study: 20170514
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of PEG‐IFN‐alpha-2a (180 ug/week) and ribavirin (800‐1200 mg/day)
Study: 15884127
Drug: Control (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (200 mL of 5% dextrose water)
Study: 12882432
Drug: Prompting intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompting intervention (weekly telephone or mail-delivered cues)
Study: 30462939
Drug: Probiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactobacillus rhamnosus R0011 and L. helveticus R0052) at a dose of 4.0×10^9 CFUs twice daily for 5 days
Study: 12632137
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.5% bupivacaine and 5 mg/ml epinephrine
Study: 23867242
Drug: Qigong intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qigong intervention (1 hour, twice per week for 4 weeks)
Study: 19302903
Drug: Multiple-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose oral SAMe (1000 mg)
Study: 19302903
Drug: Multiple-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose IV SAMe (1000 mg)
Study: 17825690
Drug: Salmeterol xinafoate/fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol xinafoate/fluticasone propionate (SFC) hydrofluoroalkane metered-dose inhaler (MDI) at 25/50 microg/actuation (group 1), 25/125 microg/actuation (group 2), or 25/250 microg/actuation (group 3), administered as 2 inhalations BID for 52 weeks.
Study: 11725825
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg cisapride orally three times daily for 7 days
Study: 9922587
Drug: TNK-t-PA (30-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNK-t-PA (30-40 mg in 15 s)
Study: 9121623
Drug: Cigarettes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes with 0.08 mg nicotine yield
Study: 9121623
Drug: Cigarettes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes with 0.17 mg nicotine yield
Study: 9121623
Drug: Cigarettes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes with 0.37 mg nicotine yield
Study: 9121623
Drug: Cigarettes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes with 0.48 mg nicotine yield
Study: 9121623
Drug: Cigarettes with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarettes with 0.74 mg nicotine yield
Study: 113129
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with all grafts patent
Study: 113129
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with all grafts closed
Study: 17414607
Drug: Preoperative hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative hepatic and regional arterial chemotherapy (PHRAC)
Study: 21624304
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human brain natriuretic peptide (rhBNP)
Study: 19139364
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) with 0.625 mg conjugated equine estrogens (CEE) with or without 2.5 mg medroxyprogesterone acetate (MPA)
Study: 11258044
Drug: Flaxin tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxin tablets 5 mg (test formulation)
Study: 2990350
Drug: MCNU and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCNU and radiation therapy
Study: 30704266
Drug: Intranasal cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cellulose powder (ICP) 250 µg thrice daily (group B)
Study: 30704266
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo 250 µg thrice daily (group C)
Study: 25046279
Drug: SFC (250/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC (250/50 μg twice daily) combined with TIO (18 μg once daily)
Study: 25046279
Drug: TIO alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIO alone (18 μg once daily)
Study: 22799589
Drug: Boceprevir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boceprevir 800 mg single dose (Day 1 and Day 4)
Study: 10464846
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol (50 micrograms b.i.d.)
Study: 2301751
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg) plus diazepam (0.3 mg/kg) 1 h before induction (group 2)
Study: 2301751
Drug: Pirenzepine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (50 mg) plus diazepam (0.3 mg/kg) on the evening before surgery and 1 h before induction (group 3)
Study: 2301751
Drug: Diazepam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.3 mg/kg) 1 h before induction (group 1)
Study: 2301751
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg) plus diazepam (0.3 mg/kg) (group 2)
Study: 2301751
Drug: Pirenzepine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (50 mg) plus diazepam (0.3 mg/kg) (group 3)
Study: 6989685
Drug: Oxamethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxamethacin (100 mg t.i.d.)
Study: 10215647
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg t.i.d.)
Study: 26284338
Drug: Taxane treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane treatment (EC/T arm)
Study: 26284338
Drug: CEF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF treatment (CEF arm)
Study: 11578885
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg propofol (Group P)
Study: 2437967
Drug: Progesterone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (25 mg vaginal suppositories twice daily)
Study: 11911755
Drug: Intravenous nesiritide
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nesiritide
Study: 12777951
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (100 mg/daily)
Study: 8558222
Drug: Standard adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjuvant therapy with high-dose chemotherapy and autologous bone marrow support (ABMT)
Study: 6134604
Drug: Propranolol 5
Normalized name: propranolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 5 mg intravenously
Study: 31116675
Drug: anti-PD-1/L1 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1/L1 antibody
Study: 26116581
Drug: Omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFAs and Aspirin
Study: 18161260
Drug: Prophylactic clotting
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic clotting factor replacement therapy, cost USD 300,000 per patient per year, started after the first episode of joint bleeding early in life.
Study: 18161260
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment started after the first episode of joint bleeding.
Study: 15321800
Drug: trans-10,cis-12 CLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: trans-10,cis-12 CLA (0.63, 1.26, and 2.52 g/d)
Study: 15321800
Drug: cis-9,trans-11 CLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis-9,trans-11 CLA (0.59, 1.19, and 2.38 g/d)
Study: 4904162
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of sustained release phenformin capsules administered twice daily
Study: 26022965
Drug: Daily PROactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily PROactive instrument
Study: 12404882
Drug: Amiloride (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (20 mg)
Study: 21508131
Drug: Intranasal amiloride-sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal amiloride-sensitive potential
Study: 7004742
Drug: Captopril 100
Normalized name: captopril 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 100 mg
Study: 15223977
Drug: Magnesium chloride
Normalized name: Magnesium Chloride
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium chloride (MgCl2) 2.5 g daily
Study: 10459960
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antihypertensive treatment)
Study: 7994795
Drug: Oral 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-fluorouracil (5-FU) (Group B)
Study: 7994795
Drug: Adriamycin and
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin and oral 5-FU (Group C)
Study: 1094994
Drug: Chloramphenicol 0.5%
Normalized name: CHLORAMPHENICOL 0.5% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol 0.5% ophthalmic solution
Study: 31619184
Drug: Medido medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medido medication dispenser
Study: 15199083
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg/day for 9 days) with olanzapine (10 mg single dose on day 4)
Study: 15199083
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg/day for 9 days) with clozapine (10 mg single dose on day 4)
Study: 8236405
Drug: ivermectin treatment
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ivermectin treatment
Study: 29769165
Drug: Potassium ferrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium ferrate haemostatic patch (PFHP)
Study: 27524882
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (wPTX) 80 mg/m² intravenously on days 1, 8, and 15, every 4 weeks
Study: 15668500
Drug: Antioxidant vitamin
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamin supplementation (500 mg vitamin C and 400 IU vitamin E daily)
Study: 12456422
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg plus dexamethasone 8 mg after induction and placebo 12 h later (Group 3)
Study: 12456422
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg plus droperidol 1.25 mg after induction and droperidol 1.25 mg 12 h later (Group 2)
Study: 10334518
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (semustine, vincristine, and fluorouracil (5-FU) - MOF regimen)
Study: 10334518
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (portal venous infusion of 5-FU)
Study: 1743824
Drug: Vodka-tonic beverage
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vodka-tonic beverage containing a dose of vodka sufficient to induce a peak blood alcohol level of 0.05%
Study: 8225624
Drug: Piperacillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (2 g)
Study: 6459764
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G (4.8 X 10(6) U)
Study: 25012577
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg clopidogrel MD with lansoprazole (30 mg/day)
Study: 17578365
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogen 0.625 mg/day (n = 35)
Study: 17578365
Drug: Intranasal 300
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 300 microg/day estradiol hemihydrate (n = 33)
Study: 17578365
Drug: Percutaneous gel
Normalized name: ALCOHOL 62 mL in 100 mL PERCUTANEOUS GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous gel 1.5 mg/day estradiol hemihydrate (n = 32)
Study: 17578365
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group, n = 32)
Study: 9563208
Drug: Sumatriptan 25
Normalized name: sumatriptan 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 25 mg
Study: 1936480
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (short and intermediate‐acting insulin before breakfast and dinner)